Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Autor: Kamel Laribi, Xavier Leleu, Nathalie Texier, Raphaël Germain, Cyrille Touzeau, Mohammad Hammoud, Alexandre Payssot, Samantha Schulmann, Ronan Le Calloch, Adrien Trebouet, Driss Chaoui, Selva David, Omar Benbrahim, Riad Benramdane, Anne Charvet‐Rumpler, Christelle Jadeau, Eglantine Rouanet, Olivier Decaux, Aurore Perrot

Publikováno v: eJHaem, Vol 5, Iss 1, Pp 55-60 (2024)

Abstract The real‐life retrospective observational study CARMYN aimed at investigating the long‐term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% i

Externí odkaz: https://doaj.org/article/c3f39a7eb9244d69938d40f26e158d2b

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Autor: Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, Villani A, Fabbrocini G

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 135-148 (2023)

Fabrizio Martora, Matteo Megna,* Teresa Battista,* Luca Potestio,* Maria Carmela Annunziata, Claudio Marasca, Alessia Villani, Gabriella Fabbrocini Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples

Externí odkaz: https://doaj.org/article/57a3cddc67344d198accd569d8523897

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Autor: Fabrizio Martora, Matteo Megna, Teresa Battista, Luca Potestio, Maria Carmela Annunziata, Claudio Marasca, Alessia Villani, Gabriella Fabbrocini

To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly va

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2467d996493f36075e353d1bbaa77f36
https://hdl.handle.net/11588/908416

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Autor: O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I. Monnet, G. Jeannin, J. Mazières, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V. Westeel, P. Brun, A. Langlais, F. Morin, P.J. Souquet, N. Girard

Publikováno v: ESMO Open
ESMO Open, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩
ESMO Open, European Society for Medical Oncology, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩

Background Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). Materials a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca79719ac7e0d0d9f96b94dc3cb9c4f
https://hal.sorbonne-universite.fr/hal-03512207/document